This is the authors' abstract. We don't add key points for this paper.
Pravastatin therapy diminished the increase of cyclooxygenase- and lipoxygenase-derived plasma lipid mediators. The identified biomarkers and related molecular pathways of inflammation and endothelial dysfunction may present potential targets for monitoring of disease severity and therapeutic intervention of autosomal dominant polycystic kidney disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Klawitter et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: